Boston, April 30, 2025 — A growing number of parents are turning to melatonin to help their children sleep, but a new review reveals we’re wading into largely uncharted territory. Use of the hormone has surged in the past decade, yet long-term safety data remain surprisingly scarce.
Melatonin for Kids: What Parents Need to Know
A comprehensive look at the risks and benefits of melatonin use in children and adolescents.
- Melatonin’s short-term effectiveness is well-established for children with neurodevelopmental disorders like autism and ADHD.
- Evidence for typically developing children is limited, with most studies focusing on older kids and adolescents.
- Commercial melatonin products often contain inaccurate dosages, and accidental ingestions are on the rise, particularly with gummy formulations.
- Melatonin should be considered a biologically active hormone, not a harmless supplement, and used only under medical supervision.
Q: Is melatonin safe for my child? A: While generally considered safe for short-term use under a doctor’s guidance, long-term effects on puberty, immune function, and neurological development are still unknown, and product quality varies widely.
Sleep disturbances are increasingly common in children and adolescents, impacting emotional regulation, cognitive development, and overall health. As families seek accessible solutions, melatonin supplements have gained popularity due to their availability and perception as a natural alternative to prescription drugs. However, melatonin isn’t a simple sleep aid; it’s a hormone that influences immune, metabolic, and reproductive systems.
Researchers at Boston Children’s Hospital conducted a narrative review, published April 30, 2025, in World Journal of Pediatrics (DOI: 10.1007/s12519-025-00896-5), examining the global rise in melatonin use among pediatric populations. The review synthesizes existing clinical evidence on effectiveness, safety, and real-world usage patterns.
The review highlights a significant gap between widespread melatonin consumption and limited long-term data. This raises concerns about inappropriate use, inconsistent product quality, and a lack of robust regulatory oversight for pediatric sleep supplements. Melatonin use has increased dramatically over the past decade, particularly in countries where it’s sold over-the-counter.
Strong Evidence for Specific Conditions
Strong evidence supports melatonin’s short-term effectiveness in children with neurodevelopmental disorders, such as autism and attention-deficit hyperactivity disorder (ADHD). In these cases, melatonin can reduce sleep-onset delay, increase total sleep time, and improve caregiver quality of life.
However, evidence for typically developing children is sparse and inconsistent. Most randomized trials involve older children or adolescents, making it difficult to draw conclusions about younger age groups where melatonin use is becoming increasingly common. Crucially, long-term safety data are lacking, leaving unanswered questions about potential effects on puberty, immune function, metabolism, and neurological development.
Outside of controlled clinical settings, safety concerns are amplified. Analyses of commercial melatonin products show a large discrepancy between labeled and actual melatonin content, with some products containing several times the stated dose or unintended compounds such as serotonin. Pediatric poison control data also indicate a sharp rise in accidental melatonin ingestions, especially among young children, often linked to appealing gummy formulations and improper storage. These findings suggest that real-world risks may be substantially underestimated.
The review emphasizes that melatonin should not be viewed as a harmless shortcut for childhood sleep problems. While it may have a role in carefully selected cases, particularly under medical supervision, it should never replace a thorough sleep evaluation or behavioral interventions. Clinicians and caregivers should recognize melatonin as a biologically active hormone, not a benign supplement.
Behavioral sleep interventions—such as consistent routines, reduced screen exposure, and age-appropriate expectations—should remain the first-line treatment for childhood insomnia. When melatonin is considered, it should be used at the lowest effective dose, for the shortest duration possible, and only under medical supervision. The review also calls for better regulation of pediatric melatonin products, clearer labeling standards, and more long-term clinical studies to ensure children receive safe, effective, and evidence-based support for healthy sleep.
What are your thoughts on melatonin use for children? Share your experiences in the comments below.
